AVEO Pharmaceuticals Inc. [NASDAQ: AVEO] plunged by -$1.09 during the normal trading session on Wednesday and reaching a high of $5.48 during the day while it closed the day at $5.16. AVEO Pharmaceuticals Inc. stock has also loss -31.38% of its value over the past 7 days. However, AVEO stock has inclined by 98.46% in the 3 months of the year. Over the past six months meanwhile, it has lost -27.32% and lost -17.35% year-on date.
The market cap for AVEO stock reached $80.55 million, with 16.08 million shares outstanding and 16.04 million shares in the current float. Compared to the average trading volume of 657.34K shares, AVEO reached a trading volume of 5001155 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about AVEO Pharmaceuticals Inc. [AVEO]:
H.C. Wainwright have made an estimate for AVEO Pharmaceuticals Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on September 11, 2019. While these analysts kept the previous recommendation, B. Riley FBR dropped their target price from $5 to $1. The new note on the price target was released on February 04, 2019, representing the official price target for AVEO Pharmaceuticals Inc. stock. Previously, the target price had yet another raise to $1, while H.C. Wainwright analysts kept a Neutral rating on AVEO stock.
The Average True Range (ATR) for AVEO Pharmaceuticals Inc. is set at 0.86, with the Price to Sales ratio for AVEO stock in the period of the last 12 months amounting to 2.88. The Price to Book ratio for the last quarter was 11.73, with the Price to Cash per share for the same quarter was set at 2.16.
AVEO stock trade performance evaluation
AVEO Pharmaceuticals Inc. [AVEO] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -31.38. With this latest performance, AVEO shares dropped by -41.36% in over the last four-week period, additionally sinking by -27.32% over the last 6 months – not to mention a drop of -28.38% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for AVEO stock in for the last two-week period is set at 33.51, with the RSI for the last a single of trading hit 23.05, and the three-weeks RSI is set at 37.93 for AVEO Pharmaceuticals Inc. [AVEO]. The present Moving Average for the last 50 days of trading for this stock 6.71, while it was recorded at 6.78 for the last single week of trading, and 6.52 for the last 200 days.
AVEO Pharmaceuticals Inc. [AVEO]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and AVEO Pharmaceuticals Inc. [AVEO] shares currently have an operating margin of -1.30. AVEO Pharmaceuticals Inc.’s Net Margin is presently recorded at +32.60.
Return on Total Capital for AVEO is now -3.34, given the latest momentum, and Return on Invested Capital for the company is 195.69. When it comes to the capital structure of this company, AVEO Pharmaceuticals Inc. [AVEO] has a Total Debt to Total Equity ratio set at 106.20. Additionally, AVEO Total Debt to Total Capital is recorded at 51.50, with Total Debt to Total Assets ending up at 31.16. Long-Term Debt to Equity for the company is recorded at 41.74, with the Long-Term Debt to Total Capital now at 20.24.
Reflecting on the efficiency of the workforce at the company, AVEO Pharmaceuticals Inc. [AVEO] managed to generate an average of $494,105 per employee. Receivables Turnover for the company is 12.37 with a Total Asset Turnover recorded at a value of 0.73.AVEO Pharmaceuticals Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.70 and a Current Ratio set at 1.70.
Earnings per share (EPS) analysis for AVEO Pharmaceuticals Inc. [AVEO] stock
With the latest financial reports released by the company, AVEO Pharmaceuticals Inc. posted -0.2/share EPS, while the average EPS was predicted by analysts to be reported at -0.65/share.When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 69.20%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for AVEO.
AVEO Pharmaceuticals Inc. [AVEO]: Insider Ownership positions
There are presently around $27 million, or 27.50% of AVEO stock, in the hands of institutional investors. The top three institutional holders of AVEO stocks are: NEA MANAGEMENT COMPANY, LLC with ownership of 2,524,387, which is approximately 0% of the company’s market cap and around 0.25% of the total institutional ownership; VANGUARD GROUP INC, holding 654,008 shares of the stock with an approximate value of $4.09 million in AVEO stocks shares; and BLACKROCK INC., currently with $1.46 million in AVEO stock with ownership of nearly 0.249% of the company’s market capitalization.
Positions in AVEO Pharmaceuticals Inc. stocks held by institutional investors increased at the end of April and at the time of the April reporting period, where 20 institutional holders increased their position in AVEO Pharmaceuticals Inc. [NASDAQ:AVEO] by around 204,350 shares. Additionally, 43 investors decreased positions by around 141,125 shares, while 5 investors held positions by with 3,963,315 shares. The mentioned changes placed institutional holdings at 4,308,790 shares, according to the latest SEC report filing. AVEO stock had 5 new institutional investments in for a total of 119,214 shares, while 30 institutional investors sold positions of 112,334 shares during the same period.